Sunday, April 24, 2011
Brain cell migration during normal development may offer insight on how cancer cells spread
Sunday, February 13, 2011
New initiative provides materials to help lower radiation dose in pediatric fluoroscopic procedures
- Pause and child-size the technique (match kVp and mAs to size of child)
- Use lowest pulse rate possible
- Limit fluoroscopic time and limit use of magnification mode
- Carefully collimate area of interest and utilize appropriate shielding
- Utilize pulsed digital fluoroscopic equipment with adjustable frame speeds and last image hold and capture capability.
- Consider ultrasound or, when applicable, MRI
- Downloadable presentation for use by providers to teach their staff methods to reduce dose and maintain quality. Radiologists are encouraged to give this talk locally
- Downloadable checklist of dose reduction steps the team should review for each patient
- Downloadable outline of dose reduction and quality maintenance steps to take in the department
- Information for pediatricians and parents regarding fluoroscopic procedures in children
- If the facility is accredited by the ACR
- If the technologists are certified or licensed, and whether they have experience with children
- How frequently the facility performs the requested fluoroscopic study in children
- If a board certified radiologist with pediatric experience, or a pediatric radiologist will be performing and interpreting the study
Thursday, August 14, 2008
Medical College of Georgia : Blood pressure response to daily stress provides clues for better hypertension treatment
How the body regulates blood pressure in response to daily stress is the focus of a study geared toward helping people whose pressure is out of control.
“Research shows that two-thirds of patients’ high blood pressure is not controlled despite the best efforts of their doctors. That is terrible,” says Dr. Gregory Harshfield, director of the Georgia Prevention Institute at the Medical College of Georgia.
“We are trying to identify the mechanisms through which blood pressure is regulated under normal everyday conditions – which is what stress is – and take that information back to the clinic to better determine what sort of therapy is going to be most effective at treating your blood pressure or your grandfather’s.”
More than a dozen researchers have teamed up to do parallel studies in animal models and young adults to learn more about what factors like genes, stress and obesity contribute, their synergy and novel ways to control them.
“This research will give us information that allows us to identify what treatment is going to be effective in what individual by genotype, by obesity and other factors. What kind of treatment is going to be effective at keeping an individual’s blood pressure down or maybe preventing it from ever getting high,” says Dr. Harshfield, principal investigator on the $10.6 million Program Project grant renewal from the National Institutes of Health’s National Heart, Lung and Blood Institute. 72 million Americans – 1 in 3 – are hypertensive, according to the NHLBI.
Studies will explore fundamentals such as why about 30 percent of young healthy blacks and 15 percent of whites can’t effectively excrete sodium, a problem that raises blood pressure by increasing the body’s fluid volume. “We think there is a defect in their kidneys, in the normal mechanisms that allow them to excrete salt,” said Dr. David Pollock, renal physiologist at MCG’s Vascular Biology Center and a program project leader. “When blood pressure goes up due to stress, their kidneys ought to get rid of more salt so their blood pressure will come down, and they don’t.”
Dr. Harshfield’s studies identified this impaired stress-induced sodium natriuresis. He believes it’s also a primary reason blood pressure remains elevated at night in some blacks, rather than dipping as it should, which keeps stressing the cardiovascular system.
Using a rat bred to be salt-sensitive, the researchers are working to identify more about the genetics of impaired sodium-handling. “We have animal model data that says the endothelin system normally functions to help your kidneys get rid of salt,” says Dr. Pollock. His studies have shown the kidney’s endothelin B receptor plays a critical role in promoting excretion of acute and chronic salt loads by activating the precursor to nitric oxide, a powerful dilator of blood vessels. In the new studies, he’ll control the rats’ diet and see whether stress slows down sodium excretion. Preliminary evidence suggests it does. He’ll also give the rats an endothelin antagonist, which blocks this hormone, and see if sodium excretion improves. He’ll also see how a high-fat diet and obesity alter the equation.
Meanwhile, for about a week, young study participants with impaired sodium excretion will take a drug to block the powerful blood vessel constrictor, angiotensin. “From our point of view, angiotensin promotes sodium retention directly and it also increases aldosterone, another hormone which promotes sodium retention,” Dr. Harshfield says. The researchers chose to study endothelin and angiotensin because they believe they work together. To explore the genetics, they’ll also look at young adults with a different version of the angiotensin receptor gene that they believe exacerbates sodium-handling problems. MCG researchers identified this genetic variation in people who retain sodium; blocking the receptor gene will provide more evidence about the importance of angiotensin, says Dr. Harshfield.
They’ll mimic the way many people work – an hour of stress, a few minutes of relief, then back to stress – by getting the young people to play competitive video games, then measuring how gene blockers affect sodium excretion. “Ultimately, you want to know how to treat people with this variation,” Dr. Harshfield says. “There is still a need to figure out why some people respond to some therapies and other don’t,” adds Dr. Pollock. “That is not our specific question but these studies will help address that. We have to identify what is it about different individuals that make them react more to stress, makes them retain more salt.”
Obesity, which is associated with increased blood pressure reactivity, is probably a differentiator, Dr. Pollock says. Fat cells actually secrete angiotensin, which gets into the bloodstream. “We are arguing in our study that you might want to treat patients differently depending on whether or not they are obese. The angiotensin receptor blocker may be more effective in obese individuals who have angiotensin falling out into their bloodstream,” says Dr. Harshfield. Consequently they’ll also compare the effectiveness of the blocker in obese and normal-weight individuals with impaired sodium excretion.
Another project is exploring the role of oxidative stress, or reactive oxygen species, in raising blood pressure. In an animal model genetically predisposed to salt-sensitive hypertension, Dr. Jennifer Pollock, biochemist in MCG’s Vascular Biology Center and a program project leader, has shown a prolonged recovery to normal blood pressure following stress. She’s also found oxidative stress levels go up with stress. Oxidative stress, or reactive oxygen species, helps make normal chemical reactions in the body but, in excess, can cause havoc. In fact, when she gives the rats an antioxidant before a stressor, blood pressure doesn’t rise as high and recovery is more normal. “We also found out that endothelin actually is the stimulus for increasing reactive oxygen species,” Dr. Jennifer Pollock says. “When we gave the rats a specific type of endothelin blocker, that also blocked the increase in oxidative stress, blocked the blood pressure increase and improved recovery.”
Now they want to know the specific sources of the reactive oxygen species. Earlier work by Dr. Frank Treiber, MCG vice president for research and principal investigator on the original Program Project grant in 2002, has shown increased blood pressure reactivity in children who are obese and/or have low socioeconomic status.
Looking at how obesity weighs in, Dr. Jennifer Pollock also is putting the rats on high-fat diets. It’s known these rats become hypertensive on a high-salt or high-fat diet and they’ve found that, as with people, fat also increases blood pressure reactivity. Now she is going to find out how.
Another animal model is providing insight into the impact of early life stressors or low socioeconomic status on cardiovascular disease. Research again found that, as with people, these animals have normal blood pressure as pups. But as stressed adult rats, they have higher pressure increases and a delayed recovery unless they are missing an endothelin receptor gene. “It cures it,” says Dr. Jennifer Pollock. “This early life stressor is being mediated through the endothelin pathway.” Her postdoctoral fellow, Dr. Analia Loria, found these early life stressor models also have more constrictive blood vessels because they are more sensitive to angiotensin. New studies will further test the endothelin connection and see if a high-fat diet makes things worse by increasing oxidative stress.
Wildlife biologists have found naturally occurring models. Rat pups whose mother builds a nest far from a food source and so must be gone foraging several hours each day, are more anxious. Neurobiologists have shown animals separated from their moms for long periods can’t run through mazes well and tend to back off in competition for food, Dr. Jennifer Pollock says. “We took that to mean their blood pressure could also be hyper reactive. Sure enough, that is what we found.”
“This has a lot of implications for earlier detection of risk-increasing environmental exposures and what you can do about it,” says Dr. Treiber, a clinical child psychologist and program project leader. “If you can’t alter the environment that quickly in life, you know now where they are headed and maybe you can preempt it pharmacogenetically.”
In the diverse group of some 600 young people he’s been following for 17 years, Dr. Treiber has found that, as with the general population, some already are obese and/or hypertensive at the average age of 25. He’ll continue to follow and annually assess them over the next five years in an effort to better understand how stress contributes to hypertension. “What we are doing is looking at chronic environmental stress in combination with some bad candidate genes that are stress activated,” says Dr. Treiber. He’s thinking that, as with rats, genetic predisposition and stress can doom people with normal pressures to hypertension. They’ll look at blood pressure reactivity, recovery, sodium secretion, measure the footprints left by oxidative stress and the levels of the stress hormone cortisol. They’ll look at early indicators of cardiovascular disease, such as enlargement of the pumping chamber of the heart and signs of carotid artery disease. “If you have a tendency to have high blood pressure or if you are obese, we can see the inner layer of the carotid getting thicker than normal people your age,” says Dr. Gaston Kapuku, cardiologist and cardiovascular researcher at the Georgia Prevention Institute and a project core leader.
America’s current obesity and type 2 diabetes epidemic also has them looking at insulin, glucose and cholesterol levels and whether fat exacerbates all the factors they are following, which they believe it does.
One reason the Georgia Prevention Institute was founded was to identify risk factors for cardiovascular disease, says Dr. Harshfield. In his 10 years at the institute, the agenda has shifted from looking at precursor development of adult hypertension to identifying mechanisms causing pediatric hypertension, a disease that didn’t exist when most hypertension textbooks were written, he says.
“Our ultimate goal, of course, is prevention,” he says. “But when we can’t do that, we want to give physicians ways to determine precisely the cause or causes of your hypertension and optimal ways to target your disease.”
The MCG Department of Biostatistics, chaired by Dr. Varghese George, is designing the studies for the Program Project grant to ensure scientifically validity and managing data for all the program projects.Tuesday, July 29, 2008
Johns Hopkins University Bloomberg School of Public Health Study Suggests 86 Percent of Americans Could be Overweight or Obese by 2030
Most adults in the U.S. will be overweight or obese by 2030, with related health care spending projected to be as much as $956.9 billion, according to researchers at the Johns Hopkins Bloomberg School of Public Health, the Agency for Healthcare Research and Quality and the University of Pennsylvania School of Medicine. Their results are published in the July 2008 online issue of Obesity.
“National survey data show that the prevalence of overweight and obese adults in the U.S. has increased steadily over the past three decades,” said Youfa Wang, MD, PhD, lead author of the study and associate professor with the Bloomberg School’s Center for Human Nutrition. “If these trends continue, more than 86 percent of adults will be overweight or obese by 2030 with approximately 96 percent of non-Hispanic black women and 91 percent of Mexican-American men affected. This would result in 1 of every 6 health care dollars spent in total direct health care costs paying for overweight and obesity-related costs.”
The researchers conducted projection analyses based on data collected over the past three decades from nationally representative surveys. Their projections illustrate the potential burden of the U.S. obesity epidemic if current trends continue.
“Our analysis also shows that over time heavy Americans become heavier,” says May A. Beydoun, a former postdoctoral research fellow at the Johns Hopkins Bloomberg School of Public Health.
“The health care costs attributable to obesity and overweight are expected to more than double every decade. This would account for 15 to 17 percent of total health care costs spent,” Wang says. “Due to the assumptions we made and the limitations of the available data, these figures are likely an underestimation of the true financial impact.”
Current standards define adults with a body mass index (BMI) between 25 and 29.9 as overweight and adults with a BMI of 30 or higher as obese. Both the overweight and obese are at an increased risk for developing a number of health conditions, including hypertension, type 2 diabetes, heart disease and stroke. Researchers estimate that children and young adults may have a shorter life expectancy than their parents if the obesity epidemic is left unaddressed.
The authors warned that obesity has become a public health crisis in the U.S. Timely, dramatic and effective development and implementation of corrective programs and policies are needed to avoid the otherwise inevitable health and societal consequences implied by their projections. If current trends continue, the researchers say that the U.S. Department of Health and Human Services will not meet its Healthy People 2010 initiative to increase the proportion of adults who are at a healthy weight and to reduce the proportion of adults who are obese.
Lan Liang, PhD; Benjamin Caballero, MD, PhD and Shiriki Kumanyika, PhD, MPH, co-authored the study “Will All Americans Become Overweight or Obese? Estimating the Progression and Cost of the U.S. Obesity Epidemic.”
The U.S. Department of Agriculture and the National Institutes of Health provided partial funding for the research.
Public Affairs media contact: Natalie Wood-Wright at 410-614-6029 or nwoodwri@jhsph.edu.
Labels: Business and Economics, Health
Posted by forhad at 4:05 AM
Public Library of Science : Sensitive testing reveals drug-resistant HIV with possible consequences for treatment
Drug-resistant HIV at levels too low to be detected by standard tests is not unusual and may contribute to treatment failure, according to research published in PLoS Medicine.
Mutations in the AIDS virus commonly occur during treatment, especially if HIV drugs are not taken consistently, and may cause treatments to fail. HIV treatment in developed countries normally includes testing for these mutations, both to select first-line drugs for a given patient and to choose second-line drugs if the virus rebounds from initial treatment. However, tests used by clinical laboratories cannot reliably detect mutant viruses that make up less than about 20% of the virus in a patient's blood.
To investigate the role of resistant virus present at lower levels, Jeffrey Johnson of the Division of HIV/AIDS Prevention Laboratory in the National Center for HIV, STD, and TB Prevention at the US Centers for Disease Control and Prevention and colleagues studied HIV from more than 500 recently infected patients in Canada and the US. Although these individuals had not received anti-HIV drugs, a highly sensitive test developed by the researchers showed that more than 10% carried HIV with common drug-resistance mutations that were not detected using usual tests.
The researchers then studied 316 samples from a separate study of about 1400 patients who were started on their first HIV treatment, which included the drug efavirenz. Before starting treatment, none of these patients had resistance to efavirenz according to standard tests. However, highly sensitive testing showed that 7 of the 95 patients who experienced treatment failure had low levels of HIV with resistance mutations to efavirenz prior to treatment. Of 211 patients whose treatment did not fail, only 2 showed low level resistance prior to treatment.
These data suggest that sensitive testing for resistance could avert failures in HIV treatment. However, given the small number of cases in this initial study, larger studies are needed to confirm the results.
In an accompanying Perspective, Steven Deeks of the University of California San Francisco, who was uninvolved with the research, discusses "whether assays for the detection of low level variants can or even should be developed for patient management." He notes that although "a sizable proportion of treatment naïve HIV infected individuals harbor a minority population of drug-resistant HIV," many patients with positive results on highly sensitive resistance testing might not go on to experience treatment failure.
Citation: Johnson JA, Li J-F, Wei X, Lipscomb J, Irlbeck D, et al. (2008) Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med 5(7): e158. doi:10.1371/journal.pmed.0050158
University of Alabama at Birmingham: Anti-HIV Therapy Boosts Life Expectancy
-
• Improvements due to modern antiretroviral cocktails
• Study underscores HIV testing, treatment needs
BIRMINGHAM, Ala. - The life expectancy for patients with human immunodeficiency virus (HIV) has increased by more than 13 years since the late 1990s thanks to advancements in antiretroviral therapy, according to researchers at the University of Alabama at Birmingham (UAB) and Simon Fraser University in Vancouver, British Columbia.
Improved survival has led to a nearly 40 percent drop in AIDS deaths among 43,355 HIV-positive study participants in Europe and North America, bolstering the call for improved anti-HIV efforts worldwide, the study authors said.
The study is published in the British medical journal The Lancet. It was compiled by The Antiretroviral Therapy Cohort Collaboration, which includes UAB, Simon Fraser University and more than a dozen other research sites around the world.
COCKTAIL OF DRUGS
The authors looked at changes in life expectancy and mortality among the 43,355 HIV patients taking a cocktail of drugs called combination antiretroviral therapy (cART). Data was compiled from a total of 14 studies in Europe and North America.
"Since their introduction in 1996 cART regimens have become more effective, better tolerated and easier to follow," said Michael Mugavero, M.D., an assistant professor in UAB's Division of Infectious Diseases and a co-author on the study.
"We are now seeing the benefits of years of research, hard work and efforts to make these medications widely available. This has led to dramatic improvements in life expectancy, but patients who start cART with more advanced HIV infection do not have the same level of benefit," Mugavero said.
The new Lancet study found cART yielded a 13.8-year life-expectancy increase - from 36.1 years in study participants who began therapy during the 1996-1999 period to 49.9 years in participants who began therapy during the 2003-2005 period.
Despite the good results, the study found life expectancy for HIV patients is far lower on average than the general population, which includes all those with other chronic illnesses. For example, an HIV-positive patient starting cART at age 20 will live to 63, about 20 years shorter than the average life span of non-infected adults.
With nearly half of all patients diagnosed with advanced HIV infection, the life expectancy benefits of cART are not fully realized, said Mugavero and lead study author Robert Hogg, Ph.D., of Simon Fraser University. Improved AIDS testing and increased access to care is needed.
Funding from the study came from the UK Research Council and from GlaxoSmithKline.
- Media Contact
- Troy Goodman
- (205) 934-8938
- tdgoodman@uab.edu
Wake Forest University Baptist Medical Center Researchers disprove long-standing belief about HIV treatment
Researchers at Wake Forest University Baptist Medical Center have disproved a long-standing clinical belief that the hepatitis C virus slows or stunts the immune system's ability to restore itself after HIV patients are treated with a combination of drugs known as the "cocktail."
Hepatitis C (HCV) infection is more serious in HIV-infected people, leading to rapid liver damage, according to the Centers for Disease Control. Intravenous drug use is a main method of contraction for both HIV and HCV and 50 to 90 percent of HIV-infected drug users are also infected with HCV.
The Wake Forest Baptist study looked at whether having HCV co-infection impairs immune restoration in patients receiving highly active anti-retroviral therapy (HAART) to suppress their HIV infection. The results appear in the July issue of AIDS Research and Human Retroviruses.
The research focused on levels of CD4 cells, the specific type of immune cell that is attacked by the HIV virus, and their ability to rebuild after HIV is suppressed.
"We've been observing that in some patients that are co-infected with hepatitis C, we were treating their HIV with HAART but didn't always get very good restoration of CD4," said Marina Nunez, M.D., lead researcher and an assistant professor of infectious diseases. "Some studies suggested it was because of the hepatitis C. This study says it's not the presence of active hepatitis C replication."
Thus, said Nunez, genetic factors involved in the immune system regulation, confounding factors associated with HCV acquisition, or other unknown factors might explain the blunted immune restoration observed in some co-infected patients. "Research efforts should pursue the role of those other factors in the immune restoration," she said.
"From a clinical standpoint, although these findings will not alter the clinical management of HIV-HCV-co-infected patients, they make clear that even after successful treatment of the HCV infection, some patients may still not get an adequate CD4 recovery under HIV treatment."
For the retrospective study, researchers examined existing medical records of 322 patients from two separate databases – one from Madrid, Spain, and the other from Wake Forest University Baptist Medical Center. Patients were separated into two groups – those co-infected with hepatitis C and HIV and those infected only with HIV. Researchers reviewed CD4 levels at baseline (before beginning HIV suppression) and every year after for up to three years, while the patients continuously received HAART, an HIV treatment consisting of three different types of medicines used by many patients, and formerly referred to as the HIV "cocktail."
Years of clinical experience have shown that, with HAART treatment suppressing the HIV, CD4 levels are typically able to restore themselves, Nunez said.
However, in some patients, it has been observed that the immune restoration is poorer after HAART. Therefore, Nunez said, it has been a common practice for doctors to attribute less than desirable CD4 restoration after HAART in co-infected patients to the hepatitis C virus.
Studies to date have found evidence both in support of and against this belief, Nunez said. But a limitation in previous studies has been that co-infected patients have been identified by the presence of HIV and the hepatitis C antibody. Since many patients with hepatitis C clear the active virus but continue to carry the antibody, there hasn't been a pure sample of patients truly co-infected with both active viruses to analyze. In this study, only patients with HIV and active hepatitis C cell replication, therefore active virus, were classified as "co-infected."
The study found that there is no difference in the CD4 restoration of co-infected patients and mono-infected patients. However, it did show some differences that seem to be associated with age, gender or past intravenous drug use.
"The purpose of this study was to find out if hepatitis C was impeding the CD4 restoration in co-infected patients," Nunez said. "And it does not. There are other factors doing it. This study says that you can look into those other factors, but we cannot blame the hepatitis C anymore."
Media Relations Contacts: Jessica Guenzel, jguenzel@wfubmc.edu, (336) 716-3487; Bonnie Davis, bdavis@wfubmc.edu or Shannon Koontz, shkoontz@wfubmc.edu, (336) 716-4587
Wake Forest University Baptist Medical Center (www.wfubmc.edu) is an academic health system comprised of North Carolina Baptist Hospital, Brenner Children's Hospital, Wake Forest University Physicians, and Wake Forest University Health Sciences, which operates the university's School of Medicine and Piedmont Triad Research Park. The system comprises 1,154 acute care, rehabilitation and long-term care beds and has been ranked as one of "America's Best Hospitals" by U.S. News & World Report since 1993. Wake Forest Baptist is ranked 32nd in the nation by America's Top Doctors for the number of its doctors considered best by their peers. The institution ranks in the top third in funding by the National Institutes of Health and fourth in the Southeast in revenues from its licensed intellectual property.
New York- Presbyterian Hospital/Columbia University Medical Center research into robotic surgery for kidney cancer
New research helps optimize benefits of robotic approach
NEW YORK (July 28, 2008) -- Clinical research at NewYork-Presbyterian Hospital/Columbia University Medical Center is helping bring the advantages of robotic surgery, including reduced pain and quicker recovery, to kidney cancer patients.
Using the latest-generation da Vinci® S Surgical System by Intuitive Surgical, surgeons operate through several small incisions in the abdomen. Surgeons then remove only the cancerous tissue from the kidney, and repair the remaining normal kidney tissue, all using robotic arms guided by video taken by a camera controlled by a separate robotic arm.
The stereoscopic view provides enhanced visibility, and the nimble robotic mechanism makes for easy cutting and suturing, according to Drs. Ketan Badani and Jaime Landman, who make up the robotic kidney surgery team at NewYork-Presbyterian/Columbia.
"With robotics, there is a much greater opportunity for complex reconstruction of the kidney than can typically be achieved with a standard laparoscopic approach," notes Dr. Badani, director of robotic urologic surgery at NewYork-Presbyterian Hospital/Columbia University Medical Center and assistant professor of urology at Columbia University College of Physicians and Surgeons.
"This means that, hopefully, we will have an opportunity not only to reduce the need for kidney cancer patients to require a kidney transplant, but also reduce their need for dialysis later in life," adds Dr. Landman, director of minimally invasive urologic surgery at NewYork-Presbyterian Hospital/Columbia University Medical Center and associate professor of urology at Columbia University College of Physicians and Surgeons.
In a recent issue of the Journal of Endourology, Dr. Badani described a new technique for port placement -- the location of the small incision through which the robot operates -- that maximizes range of motion for the robot's camera arm and working arm. The approach was shown to be successful in more than 50 cases, and has been adopted for use by medical centers worldwide.
Robotic surgery, most widely used for prostate cancer surgery, is beginning to be more widely available for other conditions. In addition to kidney cancer, Dr. Badani and Dr. Mitchell Benson (George F. Cahill Professor and Chairman of the Department of Urology at Columbia University College of Physicians and Surgeons and urologist-in-chief at NewYork-Presbyterian Hospital/Columbia University Medical Center), have established robotic surgery for bladder cancer, and they cite work being undertaken in pelvic floor reconstruction and repair of vaginal wall prolapse.
Columbia University Medical Center
Columbia University Medical Center provides international leadership in basic, pre-clinical and clinical research, in medical and health sciences education, and in patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians & Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Established in 1767, Columbia's College of Physicians & Surgeons was the first institution in the country to grant the M.D. degree and is now among the most selective medical schools in the country. Columbia University Medical Center is home to the largest medical research enterprise in New York City and state and one of the largest in the United States. For more information, please visit www.cumc.columbia.edu.
NewYork-Presbyterian Hospital
NewYork-Presbyterian Hospital, based in New York City, is the nation's largest not-for-profit, non-sectarian hospital, with 2,242 beds. The Hospital has nearly 2 million patient visits in a year, including more than 230,000 visits to its emergency departments -- more than any other area hospital. NewYork-Presbyterian provides state-of-the-art inpatient, ambulatory and preventive care in all areas of medicine at five major centers: NewYork-Presbyterian Hospital/Weill Cornell Medical Center, NewYork-Presbyterian Hospital/Columbia University Medical Center, Morgan Stanley Children's Hospital of NewYork-Presbyterian, NewYork-Presbyterian Hospital/Allen Pavilion and NewYork-Presbyterian Hospital/Westchester Division. One of the largest and most comprehensive health-care institutions in the world, the Hospital is committed to excellence in patient care, research, education and community service. It ranks sixth in U.S.News & World Report's guide to "America's Best Hospitals," ranks first on New York magazine's "Best Hospitals" survey, has the greatest number of physicians listed in New York magazine's "Best Doctors" issue, and is included among Solucient's top 15 major teaching hospitals. The Hospital's mortality rates are among the lowest for heart attack and heart failure in the country, according to a 2007 U.S. Department of Health and Human Services (HHS) report card. The Hospital has academic affiliations with two of the nation's leading medical colleges: Weill Cornell Medical College and Columbia University College of Physicians and Surgeons. For more information, visit www.nyp.org.
Blackwell Publishing : Prostate Cancer Patients Undergoing Hormone Therapy May Experience Cognitive Effects
A recent review of the literature has found that hormone deprivation therapy, a commonly used treatment for prostate cancer, may have subtle adverse effects on cognition in patients--such as in the ability to recall and concentrate. Published in the September 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that clinicians and patients should be aware of these potential effects and watch closely for their appearance.
For years, hormone deprivation therapy, also known as androgen depletion therapy, has been used as an effective treatment for prostate cancer because hormones such as testosterone drive the growth of prostate cancer cells. The most common way to achieve androgen depletion is through chemical castration with drugs such as leuprolide and goserelin. Androgen depletion therapy has traditionally been reserved for advanced cases of prostate cancer, but increasing numbers of men with earlier stages of the disease are also undergoing the treatment.
Prostate cancer patients who are prescribed these drugs often stay on them for the duration of their life, and researchers have been documenting the potential adverse effects associated with their use. Men may experience hot flashes, osteoporosis, anemia, fatigue, loss of libido, erectile dysfunction, risk of diabetes, risk of cardiovascular disease, emotional distress and other effects. Research also indicates that androgen depletion may impact cognitive functioning, which can affect a patient’s decision-making skills and quality of life.
Unfortunately, only a handful of relatively small studies have investigated the impact of androgen depletion on cognitive functioning, and some of these studies have reported contradictory results. Dr. Christian Nelson, a psychologist at Memorial Sloan-Kettering Cancer Center in New York City and his colleagues recently conducted the first review of these studies and summarized their overall results.
After performing a systematic literature search of studies in animals and humans, Dr. Nelson’s team found that testosterone and its derivatives may impact cognition via several mechanisms in the brain. For example, testosterone can modulate brain chemicals called neurotransmitters and stimulate the connections between neurons. Also, studies that have examined the impact of androgen depletion therapy in prostate cancer patients indicate that between 47 percent and 69 percent of men being treated decline in at least one cognitive area, most commonly in processes dependent on spatial ability and in high-order capacities such as the ability to multi-task.
The findings indicate that larger, more thorough studies that include brain imaging techniques are needed to better understand the nature and extent of the cognitive effects of androgen depletion.
In addition, researchers are exploring the effectiveness of using androgen depletion therapy in men with rising levels of prostate specific antigen, a potential precursor to prostate cancer. The authors concluded that “as the use of androgen depletion therapy increases, clinicians should become aware of this relationship [with cognitive decline], and inform and monitor patients for this possible side effect of treatment.”
Article: “The cognitive effects of hormone therapy in men with prostate cancer: a review.” Christian J. Nelson, Jennifer S. Lee, Maria C. Gamboa, and Andrew J. Roth. CANCER; Published Online: July 28, 2008 (DOI: 10.1002/cncr.23658); Print Issue Date: September 1, 2008.
Contact: Esther Napolitano, Media Relations Manager at Memorial Sloan-Kettering Cancer Center’s Department of Public Affairs. 212-639-3573, napolite@mskcc.org.
Blackwell Publishing : Hip Bone Density Helps Predict Breast Cancer Risk
Measuring a woman’s bone mineral density can provide additional information that may help more accurately determine a woman’s risk of developing breast cancer. That is the conclusion of a new study published in the September 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The study’s results suggest that incorporating bone mineral density tests with current risk assessments might significantly improve physicians’ ability to predict breast cancer risk in older, postmenopausal women.
Bone mineral density testing is done to diagnose osteoporosis and help assess the risk of fractures. Low bone mineral density is linked to higher risk of fractures, while normal density is linked to lower risk of fractures. It is possible that over a woman’s lifetime, hormonal and other factors that lead to higher bone mineral density can also lead to higher risk of breast cancer. Studies have found an association between higher bone mineral density and higher breast cancer risk, and bone mineral density tests have been proposed as a potential addition to breast cancer risk models. This study, supported by Eli Lilly & Company, is the first to investigate the relationships among bone mineral density, traditional breast cancer risk assessment tool results, and breast cancer incidence among the same group of postmenopausal women.
To investigate these relationships, Dr. Zhao Chen of the University of Arizona Mel and Enid Zuckerman College of Public Health and her colleagues studied approximately 10,000 post-menopausal women (average age 63) taking part in the Women’s Health Initiative, a study conducted in 40 clinical centers throughout the United States and supported by the National Heart, Lung and Blood Institute of the National Institutes of Health. The researchers assessed the women’s initial bone mineral density level as well as their score on the Gail risk model, a well known and commonly used tool that estimates five year and lifetime risk of invasive breast cancer for women 35 years of age or older. They then followed the women for an average of approximately 8 years, noting which women developed breast cancer.
As expected, the study found that women with a high Gail score had a 35 percent increased risk of developing breast cancer compared to women with a lower Gail score. But the study also found a 25 percent increase in the risk of developing the disease with each unit increase in total hip bone mineral density t-score. While the two scores were independent of each other, women who had the highest scores on both assessments had a much higher risk in breast cancer.
The findings suggest that adding bone mineral density to currently used risk assessment tools may significantly improve the prediction of breast cancer risk. “Future studies should investigate whether incorporating bone mineral density and Gail score with other risk factors, such as breast density, can further improve the identification of women at high risk for developing breast cancer,” the authors wrote. This study also suggests that bone mineral density is a potential alternative for predicting breast cancer risk in postmenopausal women if Gail score is not available. Additional studies are needed to determine if the results from this investigation are applicable to a broader group of women, including minorities. The findings do not change the use of bone mineral density testing to diagnose osteoporosis or the need to treat osteoporosis in order to reduce the risk of fractures.
Article: “Hip bone density predicts breast cancer risk independently of Gail score - results from the Women’s Health Initiative.” Zhao Chen, Leslie Arendell, Mikel Aickin, Jane Cauley, Cora E. Lewis, and Rowan Chlebowski. CANCER; Published Online: July 28, 2008 (DOI: 10.1002/cncr.23674); Print Issue Date: September 1, 2008.
Contact: Lorraine Varela - University of Arizona Mel and Enid Zuckerman College of Public Health. (520) 626-7083, varelal@coph.arizona.edu.
Cedars-Sinai Medical Center : Erectile dysfunction drugs allowed more chemotherapy to reach brain tumors in laboratory study
The drugs blocked an enzyme and opened blood vessels to tumors but not normal brain
LOS ANGELES (July 28, 2008) – In a study using laboratory animals, researchers found that medications commonly prescribed for erectile dysfunction opened a mechanism called the blood-brain tumor barrier and increased delivery of cancer-fighting drugs to malignant brain tumors.
The experiments were conducted at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute and published in Brain Research.
Viagra (sildenafil) and Levitra (vardenafil) are known as PDE5 inhibitors because they block an enzyme, phosphodiesterase5, which interrupts a series of biochemical events that cause the decreased blood flow of erectile dysfunction. This laboratory rat study, published online ahead of print in the journal, found that similar biochemical interactions in the small vessels of the brain play a major role in the blood-brain tumor barrier, which impedes delivery of anti-tumor drugs into brain tumors. PDE5 inhibitors were found to open the barrier and increase drug transport in this early animal study.
Although the normal blood-brain barrier, which regulates access to the brain from the bloodstream, shares many characteristics with the blood-brain tumor barrier, the signaling mechanism blocked by PDE5 inhibitors is unique to the blood-brain tumor barrier. This allows the PDE5 inhibitors to selectively increase drug transport to malignant brain tumors without affecting normal brain tissue.
According to the researchers, these findings may have significant implications in improving drug delivery to brain tumors in patients.
"This is the first study to show that oral administration of PDE5 inhibitors increases the rate of transport of compounds across the blood-brain tumor barrier and improves the effectiveness of the anti-tumor drug adriamycin in the treatment of brain tumors in a rat model. We chose adriamycin for this study because it is one of the most effective drugs against brain tumor cell lines in the laboratory but it has very little effect in animals and humans because it is unable to cross the blood-brain tumor barrier. The combination of vardenafil and adriamycin resulted in longer survival and smaller tumor size," said neurosurgeon Keith L. Black, M.D., chairman of the Department of Neurosurgery at Cedars-Sinai Medical Center and director of the Maxine Dunitz Neurosurgical Institute.
Black, the article's first and corresponding author, has been recognized for his earlier groundbreaking work to break through the blood-brain tumor barrier with natural and synthetic bradykinin, a peptide that temporarily opens the barrier and increases anti-cancer drug delivery into certain tumors by more than 1,000 percent. In 2000, he received the Javits Neuroscience Investigator Award from the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, for his blood-brain barrier research.
In the current studies, the blood-brain tumor barrier-opening effects of PDE5 lasted considerably longer than those of bradykinin and allowed greater transport across the barrier into tumor tissues. Because vardenafil was found to be more effective than sildenafil in increasing blood-brain tumor barrier permeability and transport, vardenafil was used in a survival study of 29 tumor-bearing rats. Those treated with saline (control) survived 32 days on average while those treated with vardenafil alone survived about 35 days and those treated with adriamycin alone survived about 42 days. When vardenafil was combined with adriamycin, rats survived an average 53 days.
Although the researchers exposed the laboratory animals to doses of sildenafil and vardenafil that are comparable to the dose range approved for erectile dysfunction in humans, there were no detectable side effects in the rats, and neither drug increased transport of tracers into normal brain tissue.
Funding for the studies was provided by the National Institute of Neurological Disorders and Stroke (the Javits Award), the Maxine Dunitz Neurosurgical Institute and the Ruth and Lawrence Harvey Chair in Neuroscience, held by Black.
Citation: Brain Research, "PDE5 Inhibitors Enhance Tumor Permeability and Efficacy of Chemotherapy in a Rat Brain Tumor Model," available online ahead of print.
American Cancer Society : Prostate cancer patients undergoing hormone therapy may experience cognitive effects
A recent review of the literature has found that hormone deprivation therapy, a commonly used treatment for prostate cancer, may have subtle adverse effects on cognition in patients-- such as in the ability to recall and concentrate. Published in the September 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that clinicians and patients should be aware of these potential effects and watch closely for their appearance.
For years, hormone deprivation therapy, also known as androgen depletion therapy, has been used as an effective treatment for prostate cancer because hormones such as testosterone drive the growth of prostate cancer cells. The most common way to achieve androgen depletion is through chemical castration with drugs such as leuprolide and goserelin. Androgen depletion therapy has traditionally been reserved for advanced cases of prostate cancer, but increasing numbers of men with earlier stages of the disease are also undergoing the treatment.
Prostate cancer patients who are prescribed these drugs often stay on them for the duration of their life, and researchers have been documenting the potential adverse effects associated with their use. Men may experience hot flashes, osteoporosis, anemia, fatigue, loss of libido, erectile dysfunction, risk of diabetes, risk of cardiovascular disease, emotional distress, and other effects. Research also indicates that androgen depletion may impact cognitive functioning, which can affect a patient's decision-making skills and quality of life.
Unfortunately, only a handful of relatively small studies have investigated the impact of androgen depletion on cognitive functioning, and some of these studies have reported contradictory results. Dr. Christian Nelson, a psychologist at Memorial Sloan-Kettering Cancer Center in New York City and his colleagues recently conducted the first review of these studies and summarized their overall results.
After performing a systematic literature search of studies in animals and humans, Dr. Nelson's team found that testosterone and its derivatives may impact cognition via several mechanisms in the brain. For example, testosterone can modulate brain chemicals called neurotransmitters and stimulate the connections between neurons. Also, studies that have examined the impact of androgen depletion therapy in prostate cancer patients indicate that between 47% and 69% of men being treated decline in at least one cognitive area, most commonly in processes dependent on spatial ability and in high-order capacities such as the ability to multi-task.
The findings indicate that larger, more thorough studies that include brain imaging techniques are needed to better understand the nature and extent of the cognitive effects of androgen depletion.
In addition, researchers are exploring the effectiveness of using androgen depletion therapy in men with rising levels of prostate specific antigen, a potential precursor to prostate cancer. The authors concluded that "as the use of androgen depletion therapy increases, clinicians should become aware of this relationship [with cognitive decline], and inform and monitor patients for this possible side effect of treatment."
Article: "The cognitive effects of hormone therapy in men with prostate cancer: a review." Christian J. Nelson, Jennifer S. Lee, Maria C. Gamboa, and Andrew J. Roth. CANCER; Published Online: July 28, 2008 (DOI: 10.1002/cncr.23658); Print Issue Date: September 1, 2008.
American Cancer Society : Hip bone density helps predict breast cancer risk
Measuring a woman's bone mineral density can provide additional information that may help more accurately determine a woman's risk of developing breast cancer. That is the conclusion of a new study published in the September 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The study's results suggest that incorporating bone mineral density tests with current risk assessments might significantly improve physicians' ability to predict breast cancer risk in older, postmenopausal women.
Bone mineral density testing is done to diagnose osteoporosis and help assess the risk of fractures. Low bone mineral density is linked to higher risk of fractures, while normal density is linked to lower risk of fractures. It is possible that over a woman's lifetime, hormonal and other factors that lead to higher bone mineral density (and lower risk of fractures) can also lead to higher risk of breast cancer. Studies have found an association between higher bone mineral density and higher breast cancer risk, and bone mineral density tests have been proposed as a potential addition to breast cancer risk models. This study, supported by Eli Lilly & Company, is the first to investigate the relationships among bone mineral density, traditional breast cancer risk assessment tool results, and breast cancer incidence among the same group of postmenopausal women.
To investigate these relationships, Dr. Zhao Chen of the University of Arizona Mel and Enid Zuckerman College of Public Health and her colleagues studied approximately 10,000 post-menopausal women (average age 63) taking part in the Women's Health Initiative, a study conducted in 40 clinical centers throughout the United States and supported by the National Heart, Lung and Blood Institute of the National Institutes of Health. The researchers assessed the women's initial bone mineral density level as well as their score on the Gail risk model, a well known and commonly used tool that estimates five year and lifetime risk of invasive breast cancer for women 35 years of age or older. They then followed the women for an average of approximately 8 years, noting which women developed breast cancer.
As expected, the study found that women with a high Gail score had a 35 percent increased risk of developing breast cancer compared to women with a lower Gail score. But the study also found a 25 percent increase in the risk of developing the disease with each unit increase in total hip bone mineral density t-score. While the two scores were independent of each other, women who had the highest scores on both assessments had a much higher risk in breast cancer.
The findings suggest that adding bone mineral density to currently used risk assessment tools may significantly improve the prediction of breast cancer risk. "Future studies should investigate whether incorporating bone mineral density and Gail score with other risk factors, such as breast density, can further improve the identification of women at high risk for developing breast cancer," the authors wrote. This study also suggests that bone mineral density is a potential alternative for predicting breast cancer risk in postmenopausal women if Gail score is not available. Additional studies are needed to determine if the results from this investigation are applicable to a broader group of women, including minorities. The findings do not change the use of bone mineral density testing to diagnose osteoporosis or the need to treat osteoporosis in order to reduce the risk of fractures.
Article: "Hip bone density predicts breast cancer risk independently of Gail score - results from the Women's Health Initiative." Zhao Chen, Leslie Arendell, Mikel Aickin, Jane Cauley, Cora E. Lewis, and Rowan Chlebowski. CANCER; Published Online: July 28, 2008 (DOI:10.1002/cncr.23674); Print Issue Date: September 1, 2008.
Harvard Medical School Being a control freak aids dividing cells
Micromanagers may generate resentment in an office setting, but they get results in your body. New data indicate that a dividing cell takes micromanagement to the extreme, tagging more than 14,000 different sites on its proteins with phosphate, a molecule that typically serves as a signal for a variety of biological processes.
This preponderance of signals suggests that the cell may become a control freak during the division process, regulating each of its parts, no matter how obscure. It may take extreme measures to ensure that each "daughter" receives a full complement of cellular material. The new data—published online the week of July 28 in PNAS—open unexplored frontiers to developmental biologists, cancer researchers, and others who study cell growth and proliferation.
"There's a massive wave of phosphorylation in dividing cells, much bigger than anyone expected," says HMS associate professor of cell biology Steven Gygi, who is corresponding author on the study. "This discovery implies that we've severely underestimated the scope of regulation in cell division for decades, which has implications for our understanding of a wide-range of diseases and developmental defects linked to the cell cycle, from cancer to holes in the heart."
Traditionally, researchers probed cell division by zooming in on a particular gene or protein and tracing its interactions. But Gygi took a different approach. A leader in the emerging field of "proteomics," which involves looking at thousands of proteins at once, his team used an instrument called a mass spectrometer to essentially take a wide-angle shot of dividing cells, capturing information that narrow studies missed. The panoramic view revealed a surprising level of signaling activity throughout the cell.
"An enormous number of proteins—more than 1,000—became highly phosphorylated during cell division, some more than 10 times," says postdoctoral researcher Noah Dephoure, who ran the experiment.
In collaboration with Chunshui Zhou, a researcher in HMS professor of genetics Stephen Elledge's lab, Dephoure worked with human cells, dividing them into two dishes. (The cells used are HeLa cells, which, while derived from a tumor, are used for many experiments because they thrive in culture. It's possible that some of the signaling events reported here are unique to these cells.) The first dish received nutrients with "heavy" carbon atoms—more massive than their "light" counterparts, which are abundant in nature. The second dish received normal nutrients, plus a toxic chemical to freeze the cells mid-division.
Dephoure and Zhou mixed all the cells together, killed them, chopped their constituent proteins—which were preserved—into small pieces called peptides, and fed these into a mass spectrometer. The instrument distinguished between otherwise identical peptides, based on the presence of "heavy" or "light" atoms, generating a ratio for each peptide. Dephoure paid particular attention to the ratios for peptides containing phosphate groups and uncovered major differences between the two populations of cells.
The dividing cells harbored a staggering number of regulated phosphate groups in unexpected places.
Gygi hypothesizes that the cell uses phosphorylation to break down every last protein complex before dividing. "Maybe the cell does something akin to putting Humpty Dumpty back together again at the end," he says.
"The massive number of phosphorylation changes in cell division strongly suggests that it involves a massive reorganization of the cell," adds HMS Department of Systems Biology chair Marc Kirschner, who was not involved in the study.
"Or the cell might phosphorylate everything to ensure that it hits a few key targets critical for proper division," says Dephoure. Under this scenario, extraneous phosphorylation may cloud the picture.
Armed with the team's list of proteins and phosphorylation sites, labs can conduct additional experiments to resolve this debate. They can investigate particular phosphorylation events and determine which ones contribute to successful regulation of cell division. Some may present therapeutic targets for patients with cell cycle diseases such as cancer.
"This study demonstrates how much a broad systematic approach to protein modification can facilitate experiments in the cell cycle field," says Kirschner. "We will be reaping results from this study for years ahead."
This research is funded by the National Institutes of Health, the Spanish Ministry of Education and Science, and Howard Hughes Medical Institute.
Fred Hutchinson Cancer Research Center : A new biomarker for early cancer detection? Research reveals that 'microRNA' may fit the bill
Scientists at Fred Hutchinson Cancer Research Center have discovered that microRNAs – molecular workhorses that regulate gene expression – are released by cancer cells and circulate in the blood, which gives them the potential to become a new class of biomarkers to detect cancer at its earliest stages. Muneesh Tewari, M.D., Ph.D., and colleagues describe their findings in the July 28 issue of the Proceedings of the National Academy of Sciences.
MicroRNAs, which act as brakes on different parts of a cell, keeping genes in check, have some advantages over protein-based early-detection systems, including that they can be detected potentially in smaller quantities and that the technology exists to rapidly develop microRNA-based early-detection tests, said Tewari, an assistant member in the Hutchinson Center's Human Biology and Clinical Research divisions. His work is focused on understanding why the brakes fail – allowing unchecked cell growth – in prostate and ovarian cancer.
"Current technology for developing tests to measure microRNAs in clinical samples is quite advanced, whereas the bottleneck for developing protein-based biomarkers is the slow process of generating assays for measuring specific proteins," he said.
The next steps, now that a proof of principle has been established, are to identify specific microRNAs that can signal the presence of a variety of solid-tumor cancers at an early stage, and to further develop the technology to detect the microRNAs in minute quantities.
For the study, Tewari and colleagues tested blood from mice and humans with advanced prostate cancers, as well as that from healthy controls. They measured microRNAs made by the tumors in both cases and controls, and they could distinguish which individuals had cancer based on blood microRNA measurement.
"This research shows that microRNAs, which weren't previously thought of as markers of cancer in the blood, are a worthwhile class of molecules to study for the purpose of early cancer detection," Tewari said.
The research that led to the surprising finding of microRNAs in plasma and serum resulted from a combination of observations and a hunch, he said.
MicroRNAs play a key role in a wide range of normal cell processes, including embryonic development and cell differentiation. The tiny regulatory molecules modulate the activity of specific messenger-RNA targets, which in turn give rise to proteins. Humans have 30,000 genes that can make messenger RNAs. There are more than 500 known microRNAs encoded by the human genome and each is thought to target up to hundreds of messenger RNAs.
That microRNAs existed in humans is in itself a recent discovery. Tewari's group initially was studying their role in cancer development and maintenance because microRNAs are often dysregulated in cancer. During the course of those experiments, the scientists found that microRNAs circulate outside of cells and are remarkably stable.
"We were surprised to discover that there are microRNAs in plasma and serum that are not associated with cells and that are not being degraded by enzymes in the blood that would degrade regular RNA," Tewari said. It isn't fully known how the microRNAs are protected from degradation or how they get into the blood.
This in turn led the researchers into a new direction of determining whether cancer-associated microRNAs could be found. Earlier studies in model organisms such as worms and flies showed that some microRNAs have specific expression in certain kinds of cells and not anywhere else.
The paper details the step-by-step approach that led to discovering microRNAs in plasma and serum components of blood, that microRNAs remain stable even after incubation at room temperature for 24 hours and after eight freeze/thaw cycles, and finally that tumor-derived microRNAs enter the circulation at levels sufficient to be measured as biomarkers for cancer.
"The results presented here establish the foundation and rationale to motivate future global investigations of microRNAs as circulating cancer biomarkers for a variety of common cancers," the authors wrote.
The availability of existing, powerful tools to characterize and measure microRNAs, such as polymerase-chain reaction technology for DNA amplification, "suggests that the discovery-validation pipeline for microRNA biomarkers will be more efficient than traditional proteomic biomarker discovery-validation pipelines, which typically encounter bottlenecks at the point of antibody and quantitative assay development for validation of biomarker candidates," the authors wrote.
In addition to those from the Hutchinson Center, scientists from the Institute for Systems Biology in Seattle, the Department of Urology at the University of Washington School of Medicine and the Department of Veterans Affairs Puget Sound Health Care System contributed to the research. The National Cancer Institute, the Pacific Ovarian Cancer Research Consortium Specialized Program of Research Excellence, the Pacific Northwest Prostate Specialized Program of Research Excellence, the Core Center of Excellence in Hematology and the Paul Allen Foundation for Medical Research funded the research.
Note to editors/reporters: Contact Dean Forbes at Fred Hutchinson Cancer Research Center to schedule interviews with Dr. Tewari and to obtain an embargoed proof copy of the paper "Circulating microRNAs as stable blood-based markers for cancer detection."
At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit fhcrc.org.
HealthGrades study Find Bariatric patients have 65% lower chance of complications at top hospitals
Better-performing hospitals have much higher volumes
Golden, CO (July, 29 2008) – Bariatric surgery patients treated at highly rated hospitals have, on average, a 65 percent lower chance of experiencing serious complications compared to patients who undergo surgery at poorly rated hospitals according to a study released today by HealthGrades, the nations leading independent healthcare ratings organization. As part of the study, the quality ratings of hospitals performing bariatric surgery in 17 states became available today at www.healthgrades.com.
HealthGrades' third annual Bariatric Surgery Trends in American Hospitals study, which evaluated bariatric surgical outcomes at every hospital that performed them in 17 states, also found that the complication rate for these surgeries continues to rise, increasing six percent from 2004 to 2006. One possible reason: lower volume facilities have higher complication rates.
Bariatric surgery is a general term describing several types of weight loss procedures. HealthGrades study analyzed the outcomes of the most common, including traditional open surgical gastric bypass procedures as well as newer, less invasive procedures such as "lap-banding" and laparoscopic gastric bypass.
Complications associated with gastric bypass surgery accounted for the highest rise in complications, increasing 17 percent. Comparatively, complications from less invasive laparoscopic surgery increased by just more than one percent. Complications associated with bariatric surgery include heart attack, kidney failure, stroke and post-surgical infections.
The HealthGrades study found a significant shift toward laparoscopic bariatric procedures. From 2004 through 2006, open gastric bypass procedures declined by 81.82 percent while during the same time period laparoscopic procedures increased 418.86 percent.
Meanwhile, the total volume of bariatric surgical procedures in the U.S. continues to grow rapidly. The American Society for Bariatric Surgery estimates that such surgeries have increased 1,431 percent in the last decade to more than 250,000 annually.
"The tremendous variation we are seeing in quality among bariatric surgery providers underscores the importance of readily available quality data to help consumers make a truly informed decision about where to seek care," said Rick May, MD, a senior physician advisor with HealthGrades and an author of the study.
Additionally, the third annual HealthGrades Bariatric Surgery Trends in American Hospitals study found that:
- A typical patient having a bariatric surgical procedure at a five-star rated hospital in one of the 17 states studied has on average, a 65 percent lower chance of experiencing one or more inhospital complications than at a one-star rated hospital and a 41 percent lower chance than at a three-star rated hospital during 2004- 2006.
- Five-star (top rated) hospitals performed almost twice the volume of procedures compared to 1-star and 3-star facilities–an average of 526 procedures from 2004 through 2006 compared with 266 and 283 respectively.
- Higher volume was associated with fewer risk-adjusted complications. Facilities with an annual case volume of 125 procedures had the lowest risk-adjusted complications. Facilities performing less than 25 cases per year had the highest rate of risk-adjusted complications.
- If all patients had received their bariatric surgery procedure at 5-star hospitals (from 2004 through 2006), 5,125 inhospital complications could have been potentially avoided in the 17 states studied.
HealthGrades Bariatric Surgery Ratings
HealthGrades' quality ratings for bariatric surgery at individual hospitals in 17 states were posted today to www.healthgrades.com as a free resource for consumers. Each hospital receives a star rating based on their patient outcomes for bariatric surgery. Hospitals with above-average outcomes receive a five-star rating. Hospitals with average outcomes receive a three-star rating, and hospitals with outcomes that are below average receive a one-star rating.
The study included a total of 154,451 bariatric inpatient surgery procedures performed in 680 hospitals in 17 states from 2004 through 2006. The majority of procedures were performed in four states: New York, Texas, Pennsylvania, and California.
- 93 hospitals stand out as "best" performers (5-star rated)
- 263 hospitals were rated as "as expected" performers (3-star rated)
- 99 hospitals were rated as "poor" performers (1-star rated)
Individuals contemplating bariatric surgery will find both quality and cost information at www.healthgrades.com. In addition to the free hospital-quality ratings, Web site visitors can also research surgeons who perform bariatric surgery as well as medical-cost reports that detail all of the costs, including out-of-pocket expenses, for the procedure.
Methodology
For this study, HealthGrades analyzed 154,451 bariatric procedures performed in the years 2004, 2005 and 2006. The states included in the study are: Arizona, California, Florida, Iowa, Maine, Maryland, Massachusetts, Nevada, New Jersey, New York, Oregon, Pennsylvania, Texas, Utah, Virginia, Washington, Wisconsin
To make accurate and valid comparisons of clinical outcomes at different hospitals with different patient characteristics, HealthGrades risk adjusted the data using multivariate logistic regression to account for age, gender and underlying medical conditions that could increase the patient's risk of mortality or complication. The full study and individual hospital ratings for bariatric surgery and other procedures can be found at www.healthgrades.com.
About HealthGrades
Health Grades, Inc. (Nasdaq: HGRD) is the leading healthcare ratings organization, providing ratings and profiles of hospitals, nursing homes and physicians. Millions of consumers and many of the nation's largest employers, health plans and hospitals rely on HealthGrades' independent ratings, advisory services and decision-support resources to make healthcare decisions based on the quality and cost of care. More information on the company can be found at http://www.healthgrades.com.
UT Southwestern Medical Center digestive specialists freeze out esophagus cancer with new therapy
| |
UT Southwestern Medical Center gastroenterologists are using a new method to freeze damaged cells in the esophagus, preventing them from turning cancerous.
The Food and Drug Administration-approved cryoablation therapy helps Barrett's esophagus patients with dysplasia, a condition in which normal cells are transformed into potentially cancerous ones.
"Due to damage from chronic stomach acid, they are people who have a higher risk of developing esophagus cancer," said Dr. Jayaprakash Sreenarasimhaiah, assistant professor of internal medicine in the division of digestive and liver disease at UT Southwestern. "The goal of this therapy is to literally freeze the damage in its tracks and stop it before it turns to cancer."
Gastroenterologists, using a special catheter, spray liquid nitrogen on the damaged tissue to freeze the superficial lining of the esophagus, the long tube that carries food from the throat to the stomach. The treated tissue eventually falls off, allowing normal cells to grow and replace the damaged cells in about six to eight weeks.
"Repeated treatments can actually help get rid of Barrett's esophagus with dysplasia and prevent the progression to cancer," said Dr. Sreenarasimhaiah, a gastroenterologist who specializes in endoscopic technology.
The minimally invasive cryoablation therapy has recently been approved by the FDA for treating Barrett's, but it requires special training and equipment available in only a handful of centers in Texas and a few dozen nationally.
Barrett's esophagus can result from ongoing heartburn, which allows a constant splashing of acid from the stomach into the esophagus. Untreated, it can become Barrett's with dysplasia, in which cells start to transform.
Typical treatment includes endoscopic mucosal resection (EMR), in which the damaged lining is scraped away, a procedure that takes hours and can have side effects such as bleeding or narrowing of the esophagus. The most aggressive approach includes surgery to remove damaged portions of the tube.
Some patients, however, are too sick or elderly to be candidates for surgery. Others simply want another option.
"This is a disease we see in a lot of older patients with other illnesses, so the decision to send them to surgery requires careful consideration," Dr. Sreenarasimhaiah said. "Cryoablation therapy is particularly attractive for older patients who may have complications or other medical issues – such as accompanying heart or lung diseases – that make traditional surgeries for Barrett's with dysplasia too risky."
Cryoablation therapy takes about 30 to 40 minutes and requires sedation. As with an endoscopy, a tube down the patient's throat is used to insert a tiny camera and instruments. No incisions are required.
Early results from studies show the therapy – similar to that used by dermatologists to freeze off warts – works well inside the esophagus, though further study is needed, Dr. Sreenarasimhaiah said.
"Patients may feel a little pain in the first couple of days, like a heartburn-type pain, but that starts to improve after a few days and after that they usually don't feel anything," he said. "They can eat immediately after they wake. They are not on a special diet, but they do continue their anti-reflux medications."
Visit http://www.utsouthwestern.org/digestive to learn more about UT Southwestern's clinical services in digestive disorders.
This news release is available on our World Wide Web home page at http://www.utsouthwestern.edu/home/news/index.html
To automatically receive news releases from UT Southwestern via e-mail, subscribe at http://www.utsouthwestern.edu/receivenews
Dr. Jayaprakash Sreenarasimhaiah -- http://www.utsouthwestern.edu/findfac/professional/0,2356,55659,00.html
Elsevier Health Sciences New study finds smoking predicts increased stroke risk for your spouse
Risk declines if spouse stops smoking
San Diego, July 29, 2008 – Although Second Hand Smoke (SHS) is widely accepted as a risk factor for coronary heart disease, there have been few studies investigating the association of SHS and stroke risk. In a new study, published in the September 2008 issue of the American Journal of Preventive Medicine, researchers report on evidence of increased risk of stroke for spouses of smokers.
For those who never smoked, being married to a current smoker was associated with a 42% increase in risk of stroke compared to being married to a never-smoker. For former smokers, being married to a current smoker was associated with a 72% increase in risk compared to being married to a never-smoker. Being married to a former smoker was not associated with any increase in risk compared to being married to a never-smoker. This suggests that although stroke risk is elevated if your spouse smokes, that risk is eliminated if your spouse stops smoking. For example, never-smokers married to former smokers had nearly the same stroke risk as never-smokers married to never-smokers. Current smokers had significantly elevated stroke rates compared to never-smokers, and spousal smoking status did not affect this risk among current smokers.
The data were drawn from the Health and Retirement Study (HRS), a National Institute on Aging sponsored longitudinal survey of U.S. adults nationwide aged ≥50 years and their spouses. Enrollments occurred in 1992, 1993, 1998 and 2004 and final analyses included 16,225 respondents. Spousal smoking status was assessed at the time of enrollment and participants were followed an average of 9.1 years after enrollment for the incidence of stroke. All models were adjusted for age; race; Hispanic ethnicity; Southern birthstate; parental education; paternal occupation class; years of education; baseline income; baseline wealth; obesity; overweight; alcohol use; and diagnosed hypertension, diabetes or heart disease.
Recent National Health and Nutrition Examination Survey (NHANES) findings for women also suggested that a husband's smoking increased the wife's risk of stroke, but in NHANES this applied only among smoking women and not among nonsmoking women. The current study found that never-smoking women married to currently smoking husbands had an increased stroke risk, compared to never-smoking women married to never-smoking husbands. This apparent discrepancy may arise from sampling differences, where NHANES participants are younger and stroke rates are lower than in HRS. Because nonsmokers have lower overall stroke risks, spousal smoking may increase stroke risk for current smokers at younger ages but emerge as a detectable risk factor for nonsmokers only at older ages.
Writing in the article, M. Maria Glymour, ScD, Harvard School of Public Health, states, "These findings indicate that spousal smoking increases stroke risk among nonsmokers and former smokers. The health benefits of quitting smoking likely extend beyond individual smokers to affect their spouses, potentially multiplying the benefits of smoking cessation."
The article is "Spousal Smoking and Incidence of First Stroke: The Health and Retirement Study" by M. Maria Glymour, ScD; Triveni DeFries; Ichiro Kawachi, MD, PhD; and Mauricio Avendano, PhD. The authors are grateful to the National Institute on Aging and the Robert Wood Johnson Foundation Health and Society Scholars Program for financial support of this research. It appears in the American Journal of Preventive Medicine, Volume 35 Issue 3 (September 2008) published by Elsevier.
Medical College of Wisconsin New study finds healthy children of Alzheimer patients show early brain changes
Medical College of Wisconsin researchers in Milwaukee have reported that children of Alzheimer's patients who are carriers of a genetic risk factor for Alzheimer's disease have neurological changes that are detectable long before clinical symptoms may appear.
Functional MRI brain imaging revealed that these symptomless carriers of the APOE-4 gene demonstrated significantly reduced functional brain connectivity between the hippocampus and the posterior cingulated cortex, two important brain structures for memory processing. These structures are relevant for information acquisition, filtering and sorting.
The study, conducted at Froedtert Hospital, was led by Shi Jiang Li, Ph.D., professor of biophysics, and was presented at the Alzheimer's Association International Conference on Alzheimer's disease in Chicago, July 29th
"Just as if cancer could be detected when there were only a few cells, decades before it was evident, the advantage of identifying those at great risk for having Alzheimer's would be of tremendous value in development of interventional therapies," says Dr. Li.
The researchers studied 28 neurologically-normal subjects, between ages 45 and 65. Twelve carried the APOE-4 gene and 16 did not. The two groups showed no significant difference in age, educational level, or neuropsychological performances. All subjects received fMRI scans. For each subject, functional connectivity between the two brain structures was measured in a resting state.
Results showed that functional connectivity in the non APOE-4 carriers was approximately 65 percent better than that of the carriers.
Other members of the research team were Piero Antuono, M.D., professor of neurology, and Zhilin Wu, Ph.D., Chunming Xie, Ph.D., and Jennifer L. Jones, M.S., research associates in the departments of biophysics and neurology.
University of Cincinnati Study Shows Residents May Benefit Most From Time in the Clinic
A new approach to internal medicine residency training could improve patient care and physician-patient relationships, according to a University of Cincinnati study.
Eric Warm, MD, associate professor of medicine and lead investigator of the study, says research showed residents who spent increased time in outpatient settings as opposed to the hospital delivered a higher quality of care and had more satisfaction in their duties.
Results of this study are published in the July edition of the Journal of General Internal Medicine.
“We essentially redesigned how the internal medicine residency runs,” says Warm. “With this new system, residents complete one year in an outpatient clinic actually doing the things patients expect from their primary care doctors. In the past, residents were based mainly in the hospital, and their delivery of care to outpatients suffered.”
Warm says in restructuring the program, he and colleagues hoped to reduce conflict between inpatient and outpatient care, provide enough time for hands-on learning and enhance the feeling of reward for residents, in addition to raising patient satisfaction and improving physician continuity.
He says there are two overall problems with current residency programs that are primarily focused on inpatient care: not enough time spent in the clinics and no tool to assess the quality of work in the clinic or ways to make it better.
“By placing our residents in the clinic, it allows them to focus on patient care,” he says. “Within the first year, both the patients’ and the residents’ satisfaction had increased.
“We utilized the chronic care model—a tool that helps improve patient care—as our central operating force.”
Instead of allowing residents to engage in “sporadic” interactions with patients for three years, this new model placed them face-to-face with the same patients for one year. During this time, they developed more intimate relationships with patients and learned how to assess and improve the quality of care they delivered.
Overall, residents reported an improvement in their ability to focus in the clinic without being distracted, an increase in personal reward and a greater sense of relationship with their patients.
Patients were also more satisfied with their care, according to Press-Ganey survey data.
Warm says there are several other legs of this study to be completed in the future, including research on the long-term impact on chronic disease.
“We hope research such as this will lead to the most optimal training for our doctors, which will benefit patients in the future,” he says.
The study is part of the Educational Innovations Project (EIP), sponsored through the Accreditation Council for Graduate Medical Education, to facilitate competency-based education and outcomes assessment in programs needing innovation.